Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy?

被引：2
|
作者：
Ackermann, Maegen A. [1 ]
机构：
[1] Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Dept Physiol & Cell Biol, Wexner Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY | 2015年 / 89卷
关键词：
UBIQUITIN-PROTEASOME SYSTEM; NF-KAPPA-B; MAMMALIAN TARGET; CARDIOMYOCYTE SURVIVAL; MYOCARDIAL-ISCHEMIA; PROTEIN-SYNTHESIS; DOWN-REGULATION; LIFE-SPAN; RAPAMYCIN; INHIBITION;
D O I：
10.1016/j.yjmcc.2015.09.014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：113 / 115
页数：3
相关论文
共 50 条
  • [21] Novel regulators and drug targets of cardiac hypertrophy
    Finckenberg, Piet
    Mervaala, Eero
    JOURNAL OF HYPERTENSION, 2010, 28 : S33 - S38
  • [22] mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets
    Watanabe, Ryosuke
    Wei, Liu
    Huang, Jing
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (04) : 497 - 500
  • [23] Transcriptional Pathways and Potential Therapeutic Targets in the Regulation of Ncx1 Expression in Cardiac Hypertrophy and Failure
    Menick, Donald R.
    Li, Mona S.
    Chernysh, Olga
    Renaud, Ludivine
    Kimbrough, Denise
    Kasiganesan, Harinath
    Mani, Santhosh K.
    SODIUM CALCIUM EXCHANGE: A GROWING SPECTRUM OF PATHOPHYSIOLOGICAL IMPLICATIONS, 2013, 961 : 125 - 135
  • [24] GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy
    Lieu, Melissa
    Koch, Walter J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (03) : 201 - 214
  • [25] Regulation of mTOR Pathway in Exercise-induced Cardiac Hypertrophy
    Liao, J.
    Li, Y.
    Zeng, F.
    Wu, Y.
    INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 2015, 36 (05) : 343 - 350
  • [26] TFEC contributes to cardiac hypertrophy by inhibiting AMPK/mTOR signaling
    Zhao, Ting
    Wang, Zhenyu
    Chi, Yehong
    Ni, Chunmei
    Zheng, Xudan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
  • [27] Selective Inhibition of the Immunoproteasome β5i Prevents PTEN Degradation and Attenuates Cardiac Hypertrophy
    Xie, Xin
    Wang, Hong-Xia
    Li, Nan
    Deng, Ya-Wen
    Bi, Hai-Lian
    Zhang, Yun-Long
    Xia, Yun-Long
    Li, Hui-Hua
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [28] Cardiac fibrosis: Pathobiology and therapeutic targets
    Czubryt, Michael P.
    Hale, Taben M.
    CELLULAR SIGNALLING, 2021, 85
  • [29] Cardiac fibrosis: potential therapeutic targets
    Park, Shuin
    Nguyen, Ngoc B.
    Pezhouman, Arash
    Ardehali, Reza
    TRANSLATIONAL RESEARCH, 2019, 209 : 121 - 137
  • [30] Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
    Bernardo, Bianca C.
    Weeks, Kate L.
    Pretorius, Lynette
    McMullen, Julie R.
    PHARMACOLOGY & THERAPEUTICS, 2010, 128 (01) : 191 - 227
12345